Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rep. DeLauro’s FDA Plans: “Restore Oversight,” Increase Budget

This article was originally published in The Gray Sheet

Executive Summary

Rep. Rosa DeLauro (D-Conn.), expected to chair the House panel overseeing FDA's budget, wants to increase agency funding, but not without the caveat of enhanced congressional oversight

You may also be interested in...



House Ag Approps Chair Threatens FDA Management On Safety Role

The chair of the House Appropriations Agriculture Subcommittee is threatening to zero-out salaries of FDA center directors and heads of offices in fiscal 2008 as a consequence of failing to follow through on safety investigations

House Ag Approps Chair Threatens FDA Management On Safety Role

The chair of the House Appropriations Agriculture Subcommittee is threatening to zero-out salaries of FDA center directors and heads of offices in fiscal 2008 as a consequence of failing to follow through on safety investigations

CDRH Unveils Postmarket Safety “Action Items”

FDA's plan to strengthen postmarket device safety by making better use of postmarket data includes modifying its organizational infrastructure, updating adverse event reporting practices and potentially increasing the use of fines for certain types of industry noncompliance

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024214

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel